[Basic and clinical aspects of calcimimetics. Treatment of secondary hyperparathyroidism in dialysis patients with calcimimetics].
Special attention has been paid to the new class of therapeutic agents namely calcimimetics for hemodialysis patients with secondary hyperparathyroidism (SHPT) . Several studies have demonstrated that calcimimetics not only reduce the concentrations of PTH, Ca, P and Ca x P but also improve bone metabolic marker and quality of life in hemodialysis patients. Recently, calcimimetics has been expected as a new strategy for SHPT in Japan. In this article, we reviewed the usefulness of calcimimetics for SHPT of dialysis patients.
Tanaka
Motoko
M
Akebono Clinic, Department of Nephrology, Japan.
Fukagawa
Masafumi
M
D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy*; D044169:Receptors, Calcium-Sensing / Q000037:antagonists & inhibitors*; D006435:Renal Dialysis
D044169:Receptors, Calcium-Sensing